Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 2928-2933

  Leonard, Steven N ^a,c,d   Vidaillac, Céline ^a   Rybak, Michael J ^a,b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DETROIT RECEIVING HOSPITAL   (United States)

^d NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; RIFAMPICIN; TELAVANCIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SIMULATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

AMINOGLYCOSIDES; GENTAMICINS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; RIFAMPIN; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 67649950672     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01544-08     Document Type: Article

References (37)

1. Akins, R. L., and M. J. Rybak. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45:454-459.
2. Barcia-Macay, M., S. Lemaire, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2006. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:1177-1184.
3. Barcia-Macay, M., F. Mouaden, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2008. Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). J. Antimicrob. Chemother. 61:1288-1294.
4. Chambers, H. F., R. T. Miller, and M. D. Newman. 1988. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann. Intern. Med. 109:619-624.
5. Charles, P. G., P. B. Ward, P. D. Johnson, B. P. Howden, and M. L. Grayson. 2004. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. 38:448-451.
6. Clinical and Laboratory Standards Institute. 2006. Methods for dilution susceptibility tests for bacteria that grow aerobically. Approved standard, 7th ed. CLSI, Wayne, PA.
7. Draghi, D. C., B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and D. F. Sahm. 2008. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:2383-2388.
8. Draghi, D. C., B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and D. F. Sahm. 2008. In vitro activity of telavancin against recent gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J. Antimicrob. Chemother. 62:116-121.
9. Fortún, J., E. Navas, J. Martinez-Beltran, J. Perez-Molina, P. Martin-Davila, A. Guerrero, and S. Moreno. 2001. Short-course therapy for rightside endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin. Infect. Dis. 33:120-125.
10. Fowler, V. G., Jr., H. W. Boucher, G. R. Corey, E. Abrutyn, A. W. Karchmer, M. E. Rupp, D. P. Levine, H. F. Chambers, F. P. Tally, G. A. Vigliani, C. H. Cabell, A. S. Link, I. DeMeyer, S. G. Filler, M. Zervos, P. Cook, J. Parsonnet, J. M. Bernstein, C. S. Price, G. N. Forrest, G. Fatkenheuer, M. Gareca, S. J. Rehm, H. R. Brodt, A. Tice, and S. E. Cosgrove. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
11. Fowler, V. G., Jr., J. M. Miro, B. Hoen, C. H. Cabell, E. Abrutyn, E. Rubinstein, G. R. Corey, D. Spelman, S. F. Bradley, B. Barsic, P. A. Pappas, K. J. Anstrom, D. Wray, C. Q. Fortes, I. Anguera, E. Athan, P. Jones, J. T. van der Meer, T. S. Elliott, D. P. Levine, and A. S. Bayer. 2005. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293:3012-3021.
12. Gander, S., A. Kinnaird, and R. Finch. 2005. Telavancin: in vitro activity against staphylococci in a biofilm model. J. Antimicrob. Chemother. 56:337-343.
13. Garnier, F., D. Chainier, T. Walsh, A. Karlsson, A. Bolmstrom, C. Grelaud, M. Mounier, F. Denis, and M. C. Ploy. 2006. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J. Antimicrob. Chemother. 57:146-149.
14. Goldstein, E. J., D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell, and H. T. Fernandez. 2004. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob. Agents Chemother. 48:2149-2152.
15. Higgins, D. L., R. Chang, D. V. Debabov, J. Leung, T. Wu, K. M. Krause, E. Sandvik, J. M. Hubbard, K. Kaniga, D. E. Schmidt, Jr., Q. Gao, R. T. Cass, D. E. Karr, B. M. Benton, and P. P. Humphrey. 2005. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:1127-1134.
16. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
17. Howden, B. P., P. D. Johnson, P. B. Ward, T. P. Stinear, and J. K. Davies. 2006. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 50:3039-3047.
18. Howden, B. P., P. B. Ward, P. G. Charles, T. M. Korman, A. Fuller, P. du Cros, E. A. Grabsch, S. A. Roberts, J. Robson, K. Read, N. Bak, J. Hurley, P. D. Johnson, A. J. Morris, B. C. Mayall, and M. L. Grayson. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528.
19. Jansen, W. T., A. Verel, J. Verhoef, and D. Milatovic. 2007. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe. Antimicrob. Agents Chemother. 51:3420-3424.
20. King, A., I. Phillips, and K. Kaniga. 2004. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration- dependent antiinfective with multiple mechanisms of action against gram-positive bacteria. J. Antimicrob. Chemother. 53:797-803.
21. Leadbetter, M. R., S. M. Adams, B. Bazzini, P. R. Fatheree, D. E. Karr, K. M. Krause, B. M. Lam, M. S. Linsell, M. B. Nodwell, J. L. Pace, K. Quast, J. P. Shaw, E. Soriano, S. G. Trapp, J. D. Villena, T. X. Wu, B. G. Christensen, and J. K. Judice. 2004. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J. Antibiot. (Tokyo) 57:326-336.
22. Leonard, S. N., and M. J. Rybak. 2008. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. Pharmacotherapy 28:458-468.
23. Leuthner, K. D., C. M. Cheung, and M. J. Rybak. 2006. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:338-343.
24. Levine, D. P., B. S. Fromm, and B. R. Reddy. 1991. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern. Med. 115:674-680.
25. Liu, C., and H. F. Chambers. 2003. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47:3040-3045.
26. Lodise, T. P., J. Graves, A. Evans, E. Graffunder, M. Helmecke, B. M. Lomaestro, and K. Stellrecht. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315-3320.
27. Madrigal, A. G., L. Basuino, and H. F. Chambers. 2005. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3163-3165.
28. Maor, Y., G. Rahav, N. Belausov, D. Ben-David, G. Smollan, and N. Keller. 2007. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J. Clin. Microbiol. 45:1511-1514.
29. Miró, J. M., C. Garcia-de-la-Maria, Y. Armero, E. de-Lazzari, D. Soy, A. Moreno, A. del Rio, M. Almela, C. A. Mestres, J. M. Gatell, M. T. Jimenez-de-Anta, and F. Marco. 2007. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 51:2373-2377.
30. Murry, K. R., P. S. McKinnon, B. Mitrzyk, and M. J. Rybak. 1999. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 19:1252-1260.
31. Rose, W. E., S. N. Leonard, and M. J. Rybak. 2008. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 52:3061-3067.
32. Rybak, M. J., B. J. Abate, S. L. Kang, M. J. Ruffing, S. A. Lerner, and G. L. Drusano. 1999. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob. Agents Chemother. 43:1549-1555.
33. Rybak, M. J., S. N. Leonard, K. L. Rossi, C. M. Cheung, H. S. Sadar, and R. N. Jones. 2008. Characterization of vancomycin heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J. Clin. Microbiol. 46:2950-2954.
34. Sakoulas, G., G. M. Eliopoulos, V. G. Fowler, Jr., R. C. Moellering, Jr., R. P. Novick, N. Lucindo, M. R. Yeaman, and A. S. Bayer. 2005. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob. Agents Chemother. 49:2687-2692.
35. Stryjewski, M. E., D. R. Graham, S. E. Wilson, W. O'Riordan, D. Young, A. Lentnek, D. P. Ross, V. G. Fowler, A. Hopkins, H. D. Friedland, S. L. Barriere, M. M. Kitt, and G. R. Corey. 2008. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin. Infect. Dis. 46:1683-1693.
36. Tenover, F. C., M. V. Lancaster, B. C. Hill, C. D. Steward, S. A. Stocker, G. A. Hancock, C. M. O'Hara, S. K. McAllister, N. C. Clark, and K. Hiramatsu. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36:1020-1027.
37. Tsuji, B. T., and M. J. Rybak. 2005. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 49:2735-2745.